ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,509.01
      0.62%
      US Tech 100
      19,483.20
      0.02%
      Dow Jones
      39,331.85
      0.00%
      Brent Oil
      86.255
      -0.22%
      Bitcoin
      60,131.24
      -3.06%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Carisma Therapeutics Inc (CARM) Quote

      Carisma Therapeutics Inc

      Carisma Therapeutics Inc (CARM)

      Carmanah Minerals Corp
      Carrefour Property Development
      1.44
      -0.23
      (-13.77%)
      Closed July 02 4:00PM
      Delayed by 15 minutes
      1.34
      -0.10
      ( -6.94% )
      Pre Market: 8:07AM
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      Key stats and details

      Current Price
      1.34
      Bid
      1.35
      Ask
      1.36
      Volume
      68,387
      0.00 Day's Range 0.00
      0.99 52 Week Range 9.7662
      Market Cap
      59.822M
      Previous Close
      1.44
      Open
      -
      Last Trade
      100
      @
      1.34
      (formt)
      Last Trade Time
      08:07:19
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      342,239
      Shares Outstanding
      41,542,744
      Dividend Yield
      -
      PE Ratio
      -0.69
      Earnings Per Share (EPS)
      -2.09
      Revenue
      14.92M
      Net Profit
      -86.88M

      About Carisma Therapeutics Inc

      Carisma Therapeutics Inc. is a clinical-stage cell therapy company. The Company is focused on utilizing the Company¿s macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The Company has created a comprehensive cell t... Carisma Therapeutics Inc. is a clinical-stage cell therapy company. The Company is focused on utilizing the Company¿s macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The Company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells. The Company¿s lead product candidate, CT-0508, is a Chimeric Antigen Receptor Macrophage (CAR-M) to be evaluated in a human clinical trial and is intended to treat solid tumors that overexpress HER2. The Company¿s second product candidate, CT-0525, is also intended to treat solid tumors that overexpress HER2, is in preclinical development. Beyond CT-0508 and CT-0525, the Company has a pipeline of cell therapy assets in various stages of pre-clinical development. The Company is also developing in vivo CAR-M gene therapies. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.carismatx.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      1970
      Carisma Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CARM. The last closing price for Carisma Therapeutics was $1.44. Over the last year, Carisma Therapeutics shares have traded in a share price range of $ 0.99 to $ 9.7662.

      Carisma Therapeutics currently has 41,542,744 shares outstanding. The market capitalization of Carisma Therapeutics is $59.82 million. Carisma Therapeutics has a price to earnings ratio (PE ratio) of -0.69.

      CARM Latest News

      More News

      CARMILA: Information Concerning the Total Number of Voting Rights and Share

      provided pursuant to article L.233-8 II of the Code de commerce (French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des marchés financiers (General regulation of...

      21 hours ago
      Business Wire

      FeaturedBNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth

      July 02 2024

      Carmila: Closing of the Acquisition of Galimmo SCA

      Carmila announces the closing of the acquisition of 93% of the share capital of Galimmo SCA Galimmo’s portfolio of 52 assets, mainly located in the North-East of France, was valued at 675...

      July 01 2024
      Business Wire

      Carisma Therapeutics Announces Changes to its Board of Directors

      Carisma Therapeutics Announces Changes to its Board of Directors PR Newswire PHILADELPHIA, July 1, 2024 Appointment of David Scadden, M.D. and Marella Thorell Resignation of Regina Hodits and...

      July 01 2024
      PR Newswire (US)

      Carmila : Participation dans Galimmo SCA potentiellement portée à 99,9%

      Regulatory News: Le 28 juin 2024, Carmila (Paris:CARM) a consenti à une entité gérée par Primonial REIM France une promesse unilatérale d’achat portant sur l’intégralité de la participation...

      July 01 2024
      Business Wire

      Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna

      Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna PR Newswire PHILADELPHIA, June 27, 2024...

      June 27 2024
      PR Newswire (US)

      Carisma Therapeutics to Participate in the Stifel 2024 Cell Therapy Forum

      Carisma Therapeutics to Participate in the Stifel 2024 Cell Therapy Forum PR Newswire PHILADELPHIA, June 25, 2024 PHILADELPHIA, June 25, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq:...

      June 25 2024
      PR Newswire (US)

      Form 4 - Statement of changes in beneficial ownership of securities

      June 18 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      June 14 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10.1815.51724137931.161.71.120324208071.4424091CS
      40.1512.60504201681.191.70.997231161.36756254CS
      12-0.54-28.72340425531.882.040.993422391.42230579CS
      26-1.47-52.31316725982.812.940.992407881.74075108CS
      52-7.55-84.92688413958.899.76620.992305533.12830875CS
      156-4.45-76.85664939555.799.76620.992409633.96499462CS
      260-4.45-76.85664939555.799.76620.992409633.96499462CS

      Market Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      VVPRVivoPower International PLC
      $ 3.43
      (128.67%)
      		13.99M
      ZCARZoomcar Holdings Inc
      $ 0.2185
      (59.96%)
      		42.07M
      CBRGChain Bridge I
      $ 17.88
      (57.26%)
      		129
      DOYUDouYu International Holdings Ltd
      $ 16.6998
      (32.64%)
      		945.1k
      ENGENGlobal Corp
      $ 1.68
      (28.24%)
      		49
      SHPWShapeways Holdings Inc
      $ 0.339
      (-51.98%)
      		93.34k
      TOIIWOncology Institute Inc
      $ 0.0185
      (-27.45%)
      		1
      RPAYRepay Holdings Corporation
      $ 8.08
      (-20.86%)
      		15
      NPCENeuropace Inc
      $ 5.76
      (-20.33%)
      		192
      STISolidion Technology Inc
      $ 0.392
      (-16.90%)
      		535.71k
      ZCARZoomcar Holdings Inc
      $ 0.2185
      (59.96%)
      		42.07M
      MAXNMaxeon Solar Technologies Ltd
      $ 0.1999
      (11.12%)
      		33.12M
      VVPRVivoPower International PLC
      $ 3.43
      (128.67%)
      		13.99M
      TSLLDirexion Daily TSLA Bull 2X Trust ETF
      $ 12.89
      (4.04%)
      		11.58M
      TSLATesla Inc
      $ 235.94
      (2.02%)
      		7M

      CARM Discussion

      View Posts
      PonkenPlonken PonkenPlonken 2 days ago
      pretty strong
      nice tech$
      👍️0
      glenn1919 glenn1919 5 days ago
      CARM.......................https://stockcharts.com/h-sc/ui?s=CARM&p=W&b=5&g=0&id=p86431144783
      👍️0
      Awl416 Awl416 6 days ago
      Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna
      👍️0
      Termite7 Termite7 1 month ago
      Could it be CARM under $0.30 ....???.......Thanks!!!
      👍️0
      axelvento axelvento 2 months ago
      $1.46 bouncer
      👍️0
      PonkenPlonken PonkenPlonken 2 months ago
      https://biomarkerres.biomedcentral.com/articles/10.1186/s40364-023-00537-x
      MRNA provides the tech, 3bln + in biobucks and has not so distant private relative with TOP tier c suite.
      👍️0
      Monksdream Monksdream 3 months ago
      CARM under $3
      👍️0
      mrplmer mrplmer 6 months ago
      Whatever happened with their acquisition of Sesn Bio and their Bladder Cancer
      👍️0
      mrplmer mrplmer 6 months ago
      Whatever happened with their acquisition of Sesn Bio and their Bladder Cancer
      👍️0
      81vette 81vette 7 months ago
      1st higher high today and bid growing now,I got some 2.64,will see if dump continues or not
      👍️0
      81vette 81vette 7 months ago
      Yea,distribution only so far today,I am watching for accumulation to start after this dumpathon,short interest went up 300% today also, 100k now,no sign of institutional buying yet,they currently hold 19%
      👍️0
      stock1ace1 stock1ace1 7 months ago
      Red on news .. we no what that means lol
      👍️0
      81vette 81vette 7 months ago
      Deal with Moderna for cancer cures,institutional might buy now lol,went up last time on this news,analysts target $9.50,short 2.45M,not optionable is good,gap filled down now,52 week low 2 weeks ago
      👍️0

      Your Recent History

      NASDAQ
      CARM
      Carisma Therapeutics
      Delayed Upgrade Clock